Higher Doses of Radiation Therapy Don’t Increase Survival in Prostate Cancer Patients, Phase 3 Trial Finds

Higher Doses of Radiation Therapy Don’t Increase Survival in Prostate Cancer Patients, Phase 3 Trial Finds
While higher doses of radiation therapy in patients with intermediate-risk prostate cancer lower the need for secondary therapies, the approach does not improve overall survival, results from a Phase 3 clinical trial show. The study, “Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer,” was published in JAMA Oncology. Optimizing radiation therapy for treatment of patients with localized prostate cancer can lead to better outcomes, as it has been shown to lower levels of prostate-specific antigen (PSA) — a marker of prostate cancer growth. However, it is not known whether higher levels of radiation therapy improve overall survival in these patients. Therefore, researchers conducted the NRG Oncology/RTOG 0126 Phase 3 clinical trial (NCT00033631), which included 1,532 patients with intermediate-risk prostate cancer at centers across North America. Patients were randomized to one of two radiation therapy regimens: either a higher dose of 79.2 gray — a standard measure of radiation — in 44 visits or the standard dose of 70.2 gray in 39 visits. After a median follow-up of 8.4 years, there were no differences in overall survival between patients in the high dose group and patients in the standard dose group. In fact, the eight-year rates of overall survival were 76% for patients i
Subscribe or to access all post and page content.

Tagged , , , , , .

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

One comment

  1. Lawrence Glickman says:

    General statements about phase 3 trials or for that matter any blanket statement like it, are not useful for patients or Doctor choices because each practitioner and patient is unique. This is proven by the government’s varying statistics on the death rates in hospitals around the country which should theoretically be identical. In this case new research has uncovered one of the problems with radiation in general as being related to “Stem cell” type cancer cells that can endure radiation. Various counter measures to these stubborn cells and the accuracy of the new MRI and Computer guided radiation treatments need to looked at specifically and in some hospitals “cure” rates are 90%. Every patient should do specific research on the success rate and protocols of the Doctor they choose.

Leave a Comment

Your email address will not be published. Required fields are marked *